Metrics as of 10/16/2026, 08:19 PM (Berlin time), refresh in progress.
Viking Therapeutics Stock
Viking Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Brian Lian
- Employees
- 65
- Market cap
- $3.2 B
- IPO
- 28/04/2015
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company specializing in the creation of novel treatments for metabolic and endocrine conditions. Headquartered in San Diego, USA, the company was founded in 2012 and currently employs 65 employees under the leadership of CEO Brian Lian. The firm…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Viking Therapeutics stock: price history
1D
-8.0%
1W
-11.7%
1M
-14.7%
6M
-28.5%
YTD
-28.5%
1Y
-27.5%
2Y
-61.8%
5Y
+318.8%
10Y
+2,088.7%
Next earnings date
Next earnings date
28/10/2026 (in 11 days)
Volatility around earnings
~16% weaker price swings than usual
Ask the agents about Viking Therapeutics
Analyst assessment of Viking Therapeutics
PRICE TARGET LOW
US$85.00
CONSENSUS
US$97.80
MEDIAN
US$95.00
PRICE TARGET HIGH
US$120.00
1
STRONG BUY
22
BUY
1
HOLD
0
SELL
0
STRONG SELL
24
TOTAL · Buy
As of: 07/10/2026
Viking Therapeutics stock metrics
P/E
-5.4
P/B
7.15
EV/EBITDA
-5.79
RETURN ON EQUITY
-31.4%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
89.4%
FLOAT SHARES
113,731,947
AVG. DAILY VOLUME (30D)
7,411,332
Insider transactions (SEC)
Kelly-Gemmell Dorothy Elizabeth
Mancini Marianna
ZANTE GREG
Mancini Marianna
Lian Brian
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -8.0%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Viking Therapeutics stock
What does Viking Therapeutics do?
Viking Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Brian Lian, the company employs around 65 people.
The IPO was on 28/04/2015; the stock trades on NASDAQ under the ticker VKTX.
What do analysts say about Viking Therapeutics stock?
24 analysts rate the stock, the consensus is Buy (as of 07/10/2026).
The average price target is US$97.80, ranging from US$85.00 to US$120.00, with a median of US$95.00.
This is an external assessment, not a statement by Market Jury.
When does Viking Therapeutics report next?
The next earnings date is 28/10/2026.
Around past earnings, price swings were roughly -16% stronger than usual.
Does Viking Therapeutics pay a dividend?
No, Viking Therapeutics currently does not pay a dividend.
Which stocks are comparable to Viking Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Viking Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Viking Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.